News

 

NEWS

Celgene acquires Delinia

Celgene acquires Delinia Three weeks after their graduation party, Delinia announced they had been acquired by Celgene for $300M upfront and up to $475M in milestones. Delinia’s co-founder and CSO, Jeff Greve, began with a single bench at QB3@953 in 2014. Less than two years later, he has delivered an exciting autoimmune candidate to Celgene – now that’s awesome!  

Read more

QB3@953 facilitates strategic alliance between innovative start up member and a sponsor company

QB3@953 facilitates strategic alliance between innovative start up member and a sponsor company Telo Therapeutics enters into an Oncology-focused research collaboration with GSK San Francisco, CA, Feb 2, 2017 – QB3@953, the Bay Area’s premier life science incubator, today announced the collaboration between one of its member companies, Telo Therapeutics, and one of its sponsor companies, GlaxoSmithKline (GSK). Telo Therapeutics […]

Read more

Servier partners with QB3@953 to find and cultivate innovative startups

Servier is the second largest French pharmaceutical company with over 3,000 researchers focused on novel treatments for cardiovascular disease, oncology, diabetes, CNS, and Rheumatology. This partnership is a boon for researchers on both sides of the Atlantic, bringing together Servier’s decades of expertise and QB3@953’s innovative thinking and startup community. Servier will receive a “golden ticket,” which allows Servier to […]

Read more

Top Place in the First Annual Diabetes Innovation Challenge

Top Place in the First Annual Diabetes Innovation Challenge Enable Biosciences was awarded top place in the First Annual Diabetes Innovation Challenge held in Boston for the most innovative late-stage (pre-clinical through translational) technology for their breakthrough ultra-sensitivity antibody assay platform. Press Release

Read more

LogicInk – Is the future of wearable health tech ….TATTOOS?

Is the future of wearable health tech ….TATTOOS? A Talk at Techonomy On November 9th 2016, LogicInk gave their first public talk as a company at a conference called Techonomy in Half Moon Bay, CA. What happens when low-cost biosensors embedded in tattoos can detect blood alcohol, sugar, or biomarkers related to diseases like malaria or zika? How will that […]

Read more

Nucleo Life Sciences

Nucleo Life Sciences will be expanding their team to broaden the number of formulation and drug development projects they are tackling. Borne out of Actera, another former QB3@953 company, Nucleo Life Sciences incubated with us for a little over one year before outgrowing our location.

Read more

Perlara PBC Announces Pharma Collaboration with Novartis

Perlara PBC Announces Pharma Collaboration with Novartis SAN FRANCISCO, Oct. 19, 2016 /PRNewswire/ Perlara PBC (previously Perlstein Lab PBC) today announced the formation of a drug discovery and development collaboration with Novartis to identify new definitive therapeutics for lysosomal storage disorders, starting with lead program Niemann-Pick Type C Disease. In addition to the collaboration, Novartis has made an equity investment […]

Read more

Amgen Incubators Grow Startup for Harvest

Amgen Incubators Grow Startup for Harvest Venture division seeks access to technology, potential takeovers. San Fernando Valley Business Journal, July 11-24, 2016 By STEPHANIE HENKEL, Staff Reporter Amgen inc. hopes to get in on more ground floors by sponsoring startups in the biotech hubs in Cambridge, Mass. and, more recently, in San Francisco. The Thousand Oaks biopharmaceutical company last month […]

Read more

Kite Pharma and Cell Design Labs Announce Exclusive Research Collaboration

Kite Pharma and Cell Design Labs Announce Exclusive Research Collaboration Using Molecular ‘On/Off Switches’ for CAR T-Cell Immunotherapies Kite to License Cell Design Labs’ Synthetic Biology Technology for Applications in Acute Myeloid Leukemia with Exclusive Option for Applications in B-cell Malignancies Cell Design Labs’ Reversible ‘On/Off Switch’ Technology Provides Dynamic Range of Control to Precisely Regulate Activity of Engineered CAR […]

Read more

Cell Design Labs Executes Series of Private Financings

Cell Design Labs Executes Series of Private Financings New Company Focused on Discovering and Developing Next-Generation Immunotherapies for Cancer and Other Complex Diseases   SAN FRANCISCO, Calif. June 2, 2016 — Cell Design Labs, Inc. today announced it has executed a staged series of investor and strategic partner financings totaling $34.4 million to fund the company’s start-up operations. The investors, […]

Read more
Page 3 of 912345...Last »

qb3at953 News

Upcoming Event

  • Tosoh Hour

    14:00-15:30
    12/14/2017
    1. HPLC Products 2. Business Development and Venture Investment Our newest sponsor Tosoh will be here on December 14th. Amongst Tosoh's interests is the Separations and Purification Division.  Their scientist, Philip Hoang, will be here and would be happy to meet with you to discuss your purification challenges. He will be joined by Toshifumi Mogami and Kenichi Haga from Tosoh's Venture and Business Development Units. Tosoh is most interested in companies working in diagnostics and research tools.  Please contact Linda Eng if you'd like to meet with them. Toshifumi Mogami, PhD, is Vice President of Business Development & Venture Investment from Tosoh USA, Inc., the venture capital arm of Tosoh Corporation. Toshifumi has a background in biophysics and bioengineering. Kenichi Haga is Senior Vice President of Business Development and Venture Investment from Tosoh USA, Inc. and his background is in organic chemistry. Philip Hoang is an Account Manager of HPLC Columns for the West Coast. He is responsible for sales and support of HPLC/UHPLC columns in California, Oregon and Washington state. Philip received his bachelor’s degree in biology from California State University, Long Beach. He has five years of technical experience in the HPLC and UHPLC field, where his work focused on the analysis of mAbs and ADCs.

Address

953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287
Map

Sign-Up for our Newsletter